Navigation Links
Ludwig Cancer Research and CRI collaborate on VentiRx's investigational immunotherapy
Date:9/3/2014

September 3, 2014, New York, NY and Seattle, WA The nonprofits Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) announced today an agreement with VentiRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company, to conduct a clinical trial with motolimod (VTX-2337) combined with other immunotherapy agents available to Ludwig and CRI through other industry partnerships. VentiRx will provide motolimod, the company's lead immuno-oncology agent, for the study, which will be conducted by Ludwig and CRI through their jointly coordinated CVC Trials Network.

"Ludwig's mission is to conduct basic, applied and clinical research to support the swift development of game-changing cancer therapies," said Jonathan Skipper, PhD, Ludwig's executive director of technology development. "Motolimod holds considerable promise as a cancer drug, particularly as a component of combination immunotherapies. We look forward to working with VentiRx to assess its potential in clinical trials, as part of our effort to bring powerful new immunotherapies as quickly as possible to cancer patients."

Immuno-oncology, as the name implies, recruits the immune system into the battle against cancer, either by boosting its existing but latent anti-tumor responses or honing its recognition of malignant cells. Several recent studies have shown that such therapies, especially when used in combination, can induce potent and durable control of advanced cancers, in some cases resulting in lasting remissions.

"Our collaboration with VentiRx is part of a broader programmatic effort to partner with top biotech and pharmaceutical companies to develop novel combinations of treatments that may work better together than each would alone," said Adam Kolom, managing director of CRI's venture fund. "By making it possible for leading academic oncologists to bring together the most promising and mechanistically distinct drugs from different companies, we are able to deliver powerful new treatments to cancer patients today while helping the field unlock immunotherapy's full potential more quickly."

Motolimod specifically binds and activates toll-like receptor-8 (TLR-8). TLR8 is found inside dendritic cells, which are patrolling immune cells that instigate, direct and fuel the immune response against infectious agents and malignant cells. When activated by motolimod, TLR-8 prompts dendritic cells within tumors to secrete factors that fuel a cascade of immune responses. This draws the innate immune system's natural killer (NK) cells into the fray, promotes the antibody-mediated destruction of malignant cells and, ultimately, supports the activation of T cells that specifically target the cancer.

"We are very excited to collaborate with Ludwig and CRI and benefit from their significant expertise in enabling this important clinical trial," said Robert Hershberg, MD, PhD, President and CEO at VentiRx. "Previous studies have shown that when motolimod (VTX-2337) is given in combination with certain chemotherapies, it enhances immune responses within the tumor microenvironment. We are confident that, as a potent activator of the innate immune response, motolimod will prove even more effective as a component of combination immunotherapy."


'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Related medicine news :

1. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
2. LSU Health New Orleans awarded grant to provide early data on cancer in kids
3. Global snapshot of infectious canine cancer shows how to control the disease
4. Breast cancer patients with bilateral mastectomy dont have better survival rates
5. ‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread
6. New Guidelines for Treating Form of Advanced Breast Cancer
7. Enzyme controlling metastasis of breast cancer identified
8. New method for non-invasive prostate cancer screening
9. DynaMed™ to Utilize Information from the National Comprehensive Cancer Network®
10. Family conflicts, other non-physical worries before cancer surgery raise patients complication risk
11. New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the game-changing ... grand opening of the Sober College Robert Pfeifer Memorial Learning Center at its ... and was attended by an overwhelming amount of alumni, family, colleagues and friends ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest edition ... to sign up as an organ donor for the 123,000 people in the United ... donor can save up to 8 saves through organ donation and enhance many others ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a ... today that a new solution for Emergency Departments (ED) has been added to ... in Emergency Department examination rooms, and with a simplified pallet of information available ...
(Date:12/9/2016)... Harrisburg, PA (PRWEB) , ... December 09, 2016 ... ... concussion education program through the Pennsylvania Cable Network (PCN) during the summer of ... Brain Injury Implementation Grant provided by the United States Department of Health and ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida ... Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This ... Only a few hospitals and facilities have earned this distinction. This is the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... DUBLIN , Dec 9, 2016 ... "High-Throughput Screening Market - Forecast to 2021" report to ... ... adoption of open innovative models in the pharmaceutical and biotechnology ... spending and rising government funding. Emerging markets and growing research ...
(Date:12/9/2016)... , Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The global travel vaccines market to grow ... The report covers the present scenario and the growth prospects of ... size, the report considers the revenue generated from the sales of ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 Australia ... GlobalData,s new report, "Australia Ophthalmic Lasers Market Outlook to ... Lasers market. The report provides value, in millions of ... within market segements - Excimer Lasers, Femtosecond Lasers and ... and distribution shares data for each of these market ...
Breaking Medicine Technology: